If you think anyone believes you have $1.2 million to invest with, I have some under water property I can sell you! Cheap! Really Cheap!!! LOl... Where do these morons come from????
Baird analyst Brian Skorney reiterated an Outperform rating and $258 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) saying an FDA authored hepatology articles provides a window into Phase 3 design.
"We're further encouraged on Intercept after the workshop manuscript from the joint meeting with the AASLD and FDA regarding endpoints in NASH trials was published in Hepatology," Skorney said. "We believe that the FDA is essentially acknowledging a path for approval in the article based on a surrogate that aligns well with the endpoint Intercept plans to target in a Phase 3 study."
For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.
Analysts at Piper Jaffray set a $20.00 price target on shares of Ocwen Financial Corp (NYSE:OCN) stock in a research report issued to clients and investors on Monday. The firm currently has a a “buy” rating on the stock. Piper Jaffray’s target price suggests a potential upside of 189.44% from the company’s current price.
OCN has been the subject of a number of other recent research reports. Analysts at Barclays lowered their price target on shares of Ocwen Financial Corp from $20.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Tuesday, January 13th. Analysts at Keefe, Bruyette & Woods set a $14.00 price target on shares of Ocwen Financial Corp and gave the company a “market perform” rating in a research note on Monday, January 5th. Analysts at Citigroup Inc. reiterated a “hold” rating and set a $15.00 price target (down previously from $23.00) on shares of Ocwen Financial Corp in a research note on Monday, December 29th. Finally, analysts at Oppenheimer reiterated a “hold” rating on shares of Ocwen Financial Corp in a research note on Tuesday, December 23rd. One analyst has rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $23.41.
Shares of Ocwen Financial Corp (NYSE:OCN) traded up 8.82% during mid-day trading on Monday, hitting $6.91. 43,430,968 shares of the company’s stock traded hands. Ocwen Financial Corp has a 52-week low of $5.66 and a 52-week high of $47.44. The stock has a 50-day moving average of $15.17 and a 200-day moving average of $23.92. The company has a market cap of $869.4 million and a price-to-earnings ratio of 4.76
Greetings from the Seeking Alpha moderation team. It turns out users often disagree regarding the investment ideas presented on the site. It has also become clear that these disagreements can spark grand debates that help readers make informed decisions. This only works however, when users keep the conversation centered on the investment thesis and do not resort to personal attacks or blanket dismissals of other users’ ideas. The comment copied below looks to contain such a personal attack and/or blanket dismissal and so, regrettably, we’re compelled to remove it.
Please understand that we do strive to err on the side of facilitating free and open debate. This means that we are never happy about having to remove a comment. That said, in order to ensure that Seeking Alpha continues to be the go-to destination for serious investment discussion, comments must adhere to our guidelines, which can be found here: http://seekingalpha.com/page/comment_guidelines?source=moddeletion
Right on queue Matt as soon as you HLF will go up in price, you & your band of thieves post a hit piece on HLF. Priceless!!! More like worthless. Matt you are spineless....
With $10 Billion in debt, very small amount of cash on hand, & with cash flow barley able to meet debt loads, its a miracle it's still trading above $7
JPMorgan (JPM) the Buyer of Ocwen's (OCN) $45B Fannie MSR Portfolio - IMF Sources
Someone just sold 3500 March $30 puts for $5.90 & bought 3500 March 35 calls for $4.50 Some one believes this is going back up
Piper Jaffray analyst Michael Grondahl reiterated an Overweight rating on Ocwen Financial Corp (NYSE: OCN) while trimming his price target to $20.00 (from $25.00) after the company ached a $2.5M settlement with California over OCN's failure to provide information to its California regulators in a timely manner.
"We believe this settlement largely removes the risk of OCN's servicing license being suspended in California," Grondahl said. "We note that California is OCN's largest state exposure by UPB at $95B and 378.1K loans. Additionally, OCN was served a notice of default on its servicing for 119 of ~4200 trusts serviced by OCN. These 119 trusts currently represent only ~$10B in servicing (originally ~$82B). We believe it is incorrect to assume that the entire servicing book will declare an event of default and pull servicing as this would greatly increase foreclosure timelines and hurt both borrowers/bondholders
Pivotal Research earlier reiterated a Buy rating on Herbalife (NYSE: HLF) with a price target of $75
You get the honor of turning out the lights. LOl...
Really? I lost money shorting YY? Hmmm sounds like u need to go back & learn basic math. Shorted YY at $66 cover at $51.20. Now how much did I lose? Lol... Dumb bag holder...
U.S. airlines expect passenger traffic to increase 2% during March and April.
The group of major carriers is forecast to show a 3% rise in capacity over the period.
The industry's net profit margin is expected to improve compared to a year ago due to lower fuel expenses.
The average price on aviation jet fuel in North America is currently down 36.6% from a year ago, but 25.2% higher than the level from a month ago.
Airline fares fell 3% in January and are expected to have shown a smaller decline in February. March fares are seen as holding steady due to strong business demand